

BY ELECTRONIC MODE

January 24, 2022

Ref No: TCPCL/SEC/2021-22/00066

<p>The General Manager, Corporate relationship department, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001 Scrip Code: 543321 Through: BSE Corporate Compliance & Listing Centre</p>	<p>The Manager, Listing department, National Stock Exchange of India Limited Exchange Plaza, C-1, Block-G, Bandra-Kurla, Complex Bandra(E), Mumbai-400 051 Scrip Symbol: TATVA Through: NEAPS</p>
---	--

Subject: Corrigendum to NOTES to Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2021.

Ref No: TCPCL/SEC/2021-22/00055 dated January 17, 2022.

Dear Sir/Madam,

With reference to above mentioned subject, we would like to inform you that there is **typographical error in point no. 6** of notes to Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2021. **The respective correction does not have any impact on financial figure/results/XBRL.**

The same has been presented below:

Note 6 to Consolidated and standalone financials to be read as:

6. The Company has completed Initial Public Offer (IPO) in July 2021, details of Statement of utilization of IPO proceeds till 31 December 2021 as per Regulation 32(1) and 32(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, are as under:

(Rupees in million)

Sl. no.	Particulars	*Amount of net proceeds as on 30.07.2021	Utilised amount up to 30.09.2021	During the quarter ended 31.12.2021	Utilised amount up to 31.12.2021	Unutilised amount as at 31.12.2021
1.	Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	1,471.00	34.75	113.25	148.00	1,323.00
2.	Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	239.71	-	1.28	1.28	238.43
3.	General corporate purposes	362.10	362.10	-	362.10	-
Total		2,072.81	396.85	114.53	511.38	1,561.43

* The amount of net proceeds..... (as is)

Factory and Registered Office : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

SEZ Unit : Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

DSIR Approved R & D Center : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533

E-mail : chintan@tatvachintan.com **Website :** www.tatvachintan.com

Earlier the same was:

6. The Company has completed Initial Public Offer (IPO) in July 2021, details of Statement of utilization of IPO proceeds till 31 December 2021 as per Regulation 32(1) and 32(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, are as under:

(Rupees in million)

Sl. no.	Particulars	*Amount of net proceeds as on 30.07.2021	Utilised amount up to 31.12.2021	Unutilised amount as at 31.12.2021
1.	Funding capital expenditure requirements for expansion of our Dahej Manufacturing Facility	1,471.00	113.25	1357.75
2.	Funding capital expenditure requirements for upgradation at our R&D facility in Vadodara	239.71	1.28	238.43
3.	General corporate purposes	362.10	362.10	-
Total		2,072.81	476.63	1,596.18


* The amount of net proceeds..... (as is)

We request you to please take the above on your records.

Thanking You,

Yours faithfully,

For Tatva Chintan Pharma Chem Limited



Ishwar Nayi
Company Secretary and Compliance Officer
M No.: A37444



Factory and Registered Office : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.

SEZ Unit : Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.

DSIR Approved R & D Center : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533

E-mail : chintan@tatvachintan.com **Website :** www.tatvachintan.com